论文部分内容阅读
Sudden cardiac death (SCD) claims the lives of more than 400 000 persons each year in the United States.1 The implantable cardioverter defibrillator has been shown in randomized, controlled trials to prevent SCD in patients with prior myocardial infarction (MI) and reduced left ventricular (LV) function.>" At the present time, measuring the LV ejection fraction (L VEF) is the primary method for risk stratification for SCD in patients with coronary artery disease (CAD)."